Physician profile
Deepinder Goyal
NPI 1538323399
$9,208.72
in general payments reported to CMS, 2019-2025
42 companies · $1,836 in 2025
The $1,836 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $705 · 2021: $716 · 2022: $495 · 2023: $2,988 · 2024: $2,022 · 2025: $1,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,541 · Consulting Fee: $1,250 · Education: $54.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,541.41 |
| Consulting Fee | $1,250.00 |
| Education | $54.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,376.74 | 2019-2025 | |
| Ardelyx, INC. | $1,559.03 | 2023-2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,211.55 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Janssen Biotech, INC. | $583.08 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $435.24 | 2019-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $312.39 | 2023-2025 | Voquezna |
| Boston Scientific Corporation | $226.53 | 2021-2025 | Axonics |
| Intercept Pharmaceuticals, INC. | $184.86 | 2019-2024 | Ocaliva |
| Redhill Biopharma INC. | $181.19 | 2020-2022 | |
| Intra-Sana Laboratories | $171.75 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Genzyme Corporation | $165.28 | 2024-2025 | |
| Medtronic, INC. | $136.74 | 2025 | Interstim |
| Olympus America INC. | $115.48 | 2020 | |
| Gilead Sciences, INC. | $113.80 | 2025 | Livdelzi |
| Pentax of America, INC. | $105.53 | 2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $103.52 | 2024-2025 | Zenpep |
| Angiodynamics, INC. | $103.12 | 2019 | |
| Pfizer INC. | $96.80 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $89.42 | 2025 | Tremfya |
| Ironwood Pharmaceuticals, INC | $82.34 | 2020-2025 | |
| Lilly USA, LLC | $69.15 | 2025 | Omvoh |
| Cook Medical LLC | $68.55 | 2020-2021 | |
| Qol Medical, LLC | $67.59 | 2023 | Sucraid |
| Enterra Medical, INC. | $63.75 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $62.70 | 2025 | Iqirvo |
| Ambu INC. | $55.56 | 2024 | |
| Novo Nordisk INC | $50.70 | 2025 | Wegovy, Ozempic |
| Ferring Pharmaceuticals INC. | $46.66 | 2021-2023 | Rebyota |
| Braintree Laboratories, INC. | $41.67 | 2019-2025 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $39.13 | 2022-2023 | Dificid |
| Vivus LLC | $37.50 | 2022-2025 | Pancreaze |
| Nestle Healthcare Nutrition INC. | $34.84 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $34.41 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $30.57 | 2024 | Zymfentra |
| Madrigal Pharmaceuticals | $29.04 | 2024 | Resmetirom |
| Fresenius Kabi USA, LLC | $24.10 | 2023 | |
| Baxter Healthcare | $23.37 | 2024 | Renal - Pd |
| Celgene Corporation | $19.18 | 2022 | |
| Capsovision, INC. | $17.32 | 2023 | Capsocam Plus |
| Shionogi INC | $16.63 | 2019 | |
| Ucb, INC. | $11.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepinder Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.